We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Targeted Fluorescent-Imaging Compound Detects Viable Cancer Cells

By LabMedica International staff writers
Posted on 19 Jan 2009
A fluorescent-imaging compound is turned on only when it is inside a living cell and stops fluorescing when the cell dies or becomes damaged. More...
The compound can be engineered to target specific types of cancer cells.

The new compound enabled scientists to visualize viable breast cancer cells that have spread to the lungs in mice. The compound binds to a protein called HER2, which is found on the surface of some breast cancer cells, and it glows, or fluoresces, only when taken into living cells. This method of targeting and activation allowed the scientists to detect specific types of live cancer cells in a mouse model of breast cancer.

Previously developed fluorescent compounds that are activated inside the body's cells have the limitation that once turned on they continue to fluoresce even after they diffuse to new locations. This makes it very difficult to distinguish viable tumor cells from normal tissue, dead, or damaged tumor cells.

The investigation took place at the National Cancer Institute (NCI), part of the US National Institutes of Health (Bethesda, MD, USA) and in Japan. The scientific team that created the imaging compound was led by Hisataka Kobayashi, M.D., Ph.D., from NCI's Center for Cancer Research (CCR), in collaboration with Yasuteru Urano, Ph.D., from the University of Tokyo (Japan).

"These [fluorescing-imaging] compounds may allow clinicians to monitor a patient's response to cancer therapy by allowing them to visualize whether a drug hits its target and whether hitting the target leads to shrinkage of the tumor," said Dr. Kobayashi. He added, "Our design concept is very versatile and can be used to detect many types of cancer. Unlike other activatable fluorescent compounds, our compound consists of a targeting agent and a fluorescing agent that act independently. We can target the fluorescing agent to different types of cancer cells by using any antibody or molecule that is internalized by the targeted cells after it binds to the cell's surface proteins."

The new compound was described online in Nature Medicine on December 7, 2008.

Related Links:

US National Institutes of Health
University of Tokyo



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.